Surgeries and physical interventions in the treatment of cerebral palsy spasticity
DOI:
https://doi.org/10.11606/issn.2317-0190.v17i2a103315Keywords:
Muscle Spasticity, Cerebral Palsy, Botulinum Toxin Type AAbstract
Although the espasticidade treatment in patients with cerebral palsy is based essentially on cinesioterapia and drugs administrated as chemical blockades infiltration or orally, there are situations where such aid does
not have the desired effect, either because of the seriousness of the espasticidade or contra-indications and adverse effects of the botulinum toxin. We can also see human musculoskeletal apparatus deformities resulting from constant deforming stimulus of espasticidade and amendment biomechanics that it imposes on the member positioning during the gait, ortostatismo or other rest positions. In this situation, are indicated surgical procedures which aim at improving the condition of positioning biomechanics, adequacy and efficiency of movement in general. This review article has the aim to provide alternative forms of drug administration for the control of espasticidade, as baclofen bump that requires a chirurgical procedure and others indications and surgeries for the control of espasticidade and its consequences as deformities.
We will discuss also the indications for physiotherapy procedures and ortheses indications with the indication to reduce spasticity.
Downloads
References
Jacobs JM. Management options for the child with spastic cerebral palsy. Orthop Nurs. 2001;20(3):53-9.
Matthews DJ, Balaban B. Management of spasticity in children with cerebral palsy. Acta Orthop Traumatol Turc. 2009;43(2):81-6.
Chambers HG. Advances in Cerebral Palsy. Curr Opin Orthop. 2002;13(6):424-31.
Téllez de Meneses M, Barbero P, Alvarez-Garijo JA, Mulas F. Intrathecal baclofen and Botulinum toxin in infantile cerebral palsy. Rev Neurol. 2005;40(Suppl 1):S69-73.
Elovic E. Principles of pharmaceutical management of spastic hypertonia. Phys Med Rehabil Clin N Am. 2001;12(4):793-816, vii.
Tilton AH. Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol. 2004;11(1):58-65.
Tilton A. Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol. 2009;16(2):82-9.
Patel DR, Soyode O. Pharmacologic interventions for reducing spasticity in cerebral palsy. Indian J Pediatr. 2005;72(10):869-72.
Tilton AH. Therapeutic interventions for tone abnormalities in cerebral palsy. NeuroRx. 2006;3(2):217-24.
Mooney JF 3rd, Koman LA, Smith BP. Pharmacologic management of spasticity in cerebral palsy. J Pediatr Orthop. 2003;23(5):679-86.
Flett PJ. Rehabilitation of spasticity and related problems in childhood cerebral palsy. J Paediatr Child Health. 2003;39(1):6-14.
Kopec K. Cerebral palsy: pharmacologic treatment of spasticity. US Pharm. 2008;33(1):22-6.
Brashear A, Lambeth K. Spasticity. Curr Treat Options Neurol. 2009;11(3):153-61.
Albright AL, Barry MJ, Shafton DH, Ferson SS. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol. 2001;43(10):652-7.
Papavasiliou AS. Management of motor problems in cerebral palsy: a critical update for the clinician. Eur J Paediatr Neurol. 2009;13(5):387-96.
Heinen F, Molenaers G, Fairhurst C, Carr LJ, Desloovere K, Chaleat Valayer E, et al. European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2006;10(5-6):215-25.
Rodda J, Graham HK. Classification of gait patterns in spastic hemiplegia and spastic diplegia: a basis for a management algorithm. Eur J Neurol. 2001;8(Suppl 5):98-108.
Gormley ME Jr. Treatment of neuromuscular and musculoskeletal problems in cerebral palsy. Pediatr Rehabil. 2001;4(1):5-16.
Sharan D. Recent advances in management of cerebral palsy. Indian J Pediatr. 2005;72(11):969-73.
McLaughlin J, Bjornson K, Temkin N, Steinbok P, Wright V, Reiner A, et al. Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials. Dev Med Child Neurol. 2002;44(1):17-25.
Graham HK; Selber P. Musculoskeletal aspects of cerebral palsy. J Bone Joint Surg, 2003;85B(2):157-66.
Ward AB, Molenaers G, Colosimo C, Berardelli A. Clinical value of botulinum toxin in neurological indications. Eur J Neurol. 2006 ;13(Suppl 4):20-6.
Damiano DL, Alter KE, Chambers H. New clinical and research trends in lower extremity management for ambulatory children with cerebral palsy. Phys Med Rehabil Clin N Am. 2009;20(3):469-91.
Gormley ME Jr, Krach LE, Piccini L. Spasticity management in the child with spastic quadriplegia. Eur J Neurol. 2001;8 Suppl 5:127-35.
Jozefczyk PB. The management of focal spasticity. Clin Neuropharmacol. 2002;25(3):158-73.
Yaggie J, Armstrong W. Spastic diplegic cerebral palsy: a brief introduction to its characteristics, assessment and treatment options. Clin Kinesiol. 2001;55(4):75-80.
Boyd RN, Morris ME, Graham HK. Management of upper limb dysfunction in children with cerebral palsy: a systematic review. Eur J Neurol. 2001;8 Suppl 5:150-66.
Ong HT, Chong HN, Yap SSP. Comprehensive management of spasticity in cerebral palsy: role of physical therapy and other adjunctive treatments. Singapore Paediatr J. 2001;43(4):133-6.
Tilton AH. Approach to the rehabilitation of spasticity and neuromuscular disorders in children. Neurol Clin. 2003;21(4):853-81, vii.
Ward AB. Spasticity treatment with botulinum toxins. J Neural Transm. 2008;115(4):607-16.
Brunstrom JE, Clinical considerations in cerebral palsy and spasticity. J Child Neurol. 2001;16(1):10-5.
Molenaers G, Desloovere K, Eyssen M, De Cat J, Jonkers I, De Cock P. Botulinum toxin type A treatment of cerebral palsy: an integrated approach. Eur J Neurol. 1999;6:(Suppl 4):S51-7.
O'Brien CF. Treatment of spasticity with botulinum toxin. Clin J Pain. 2002;18(6 Suppl):S182-90.
Yablon SA. Botulinum neurotoxin intramuscular chemodenervation. Role in the management of spastic hypertonia and related motor disorders. Phys Med Rehabil Clin N Am. 2001;12(4):833-74,vii-viii.
Downloads
Published
Issue
Section
License
Copyright (c) 2010 Acta Fisiátrica
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
